Sigma-Aldrich signs exclusive distribution agreement with Roche

Published: 19-Mar-2015
Ingredients

Provides researchers with global access to Roche biochemical reagents


Sigma-Aldrich has agreed, in an exclusive deal, to distribute Roche's Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR (polymerase chain reaction) applications.

Eric Green, Executive Vice President and President, Sigma-Aldrich Research, said the addition of these life science tools 'supports our strategy to augment our portfolio with products that accelerate customer scientific research programmes'.

Transfer of the Roche portfolio to Sigma-Aldrich will take place during 2015. In the interim, these products will continue to be available through existing Roche channels.

  • Companies:
  • Roche Group
  • Merck Electronics KGaA
See more

You may also like

Ingredients

Merck expands granulated excipient line for pharma products

Read more
The company has launched a multi-compendial excipient with broad application in both pharma and biopharma

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Merck expands granulated excipient line for pharma products

The company has launched a multi-compendial excipient with broad application in both pharma and biopharma
Manufacturing

MilliporeSigma adds full viral vector contract services with new platform

This new launch has made it one of the first CDMOs and technology developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development
Manufacturing

Merck opens $63m CDMO facility to handle HPAPIs

The industry expert has announced that its Life Science business sector has doubled its highly potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of this facility
Ingredients

Therapeutics: tepotinib for lung cancer

Lung cancer is the most common type of cancer, with an estimated 2 million cases being diagnosed every year and 1.7 million deaths recorded
Ingredients

Managing the unavoidable: A practical approach to handling TUPs

Technically unavoidable particles (TUPs) are found in chemical raw materials, such as excipients. They do not pose a risk to patient safety, but can create problems if not managed well. Merck KGaA's Dr Torsten Schadendorf and Jennifer Standare explain
Ingredients

Merck makes nanoparticle-reduced sucrose with new filtration process

The product is based on a new filtration-based manufacturing process for reduced levels of nanoparticle impurities in biopharmaceutical formulations
Ingredients

Therapeutics: evobritinib for multiple sclerosis

There is a growing body of evidence suggesting that, as well as regulating normal autoimmunity, B-cells are also involved in immune-mediated diseases, including multiple sclerosis (MS)
Subscribe now